Showing results (471-480 of 535) with videos related to
Sort By:
Pageof 54
Journal of Hematology & Oncology|June 17, 2026
Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasmsSankalp Arora, Jayastu Senapati, Indraneel Deshmukh, et al.Journal of Hematology & Oncology|January 30, 2022
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposureNicholas J Short, Sangeetha Venugopal, Wei Qiao, et al.Cancer|August 3, 2021
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysisAbhishek Maiti, Courtney D DiNardo, Wei Qiao, et al.Blood Advances|April 22, 2021
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclaxCurtis A Lachowiez, Sanam Loghavi, Ken Furudate, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2023
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid MalignanciesJayastu Senapati, Warren C Fiskus, Naval Daver, et al.Blood Cancer Journal|June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisJayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.Blood Advances|May 27, 2026
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AMLNicholas J Short, Hagop M Kantarjian, Naval G Daver, et al.Blood Advances|August 16, 2022
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndromeCourtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, et al.Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.BMJ Open|March 21, 2024
Comprehensive quality assessment for aphasia rehabilitation after stroke: protocol for a multicentre, mixed-methods studySam Harvey, Marissa Stone, Sally Zingelman, et al.Pageof 54